Marché mondial du traitement de l’hypoparathyroïdie – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché du traitement de l'hypoparathyroïdie

L'hypoparathyroïdie touche environ 200 000 personnes, dont la majorité des cas sont associés à des lésions accidentelles ou à l'ablation de la glande parathyroïde lors d'une chirurgie thyroïdienne. D'autres cas sont liés à des problèmes auto-immuns, héréditaires et idiopathiques. Le traitement standard actuel implique l'utilisation d'analogues du calcium et de la vitamine D. Le développement de médicaments personnalisés, l'augmentation rapide de la demande de produits biologiques pour l'hypothyroïdie et la fusion des activités des acteurs du marché créeront des opportunités majeures pour l'expansion du marché du traitement de l'hypothyroïdie

Data Bridge Market Research analyse le taux de croissance du marché mondial du traitement de l'hypoparathyroïdie au cours de la période de prévision 2022-2029. Le TCAC attendu du marché mondial du traitement de l'hypoparathyroïdie a tendance à être d'environ 8,50 % au cours de la période de prévision mentionnée. Le marché était évalué à 0,86 milliard USD en 2021 et devrait atteindre 1,65 milliard USD d'ici 2029. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché du traitement de l'hypoparathyroïdie

Market Definition

Hypoparathyroidism is a type of condition that occurs when the parathyroid glands fail to produce sufficient levels of parathormone (PTH). The primary function of PTH is to regulate calcium and phosphate. When there isn’t enough of these nutrients in blood, it can lead to multiple problems like bone thinning and bone pain. Nerve problems can result in causing symptoms like? numbness, tingling, or even seizures. Patients also might feel restless all the time that is caused by a lack of calcium levels.

Global Hypoparathyroidism Treatment Market Dynamics

Drivers

• Increased Incidence of Parathyroid Disorders

Thyroid Disorders, mainly hyperthyroidism, affect 200 million people worldwide; in most countries, half of the population remains undiagnosed. This condition is more predominant among women and the elderly. Rise in incidence of parathyroid diseases is projected to boost the growth of the global hypoparathyroidism treatment market. Recently, a study stated that between 2003 and 2017, it is projected that 13,897 admissions accounting to 12,903 patients registered with parathyroid gland disorder were stated in Spain. According to the reports of Informa U.K. Limited, primary hyperparathyroidism (pHPT) is the third most common endocrine disorder. This boosts the market growth.

• Rising Demand for Oral Drugs

Oral drugs is anticipated to boost the market growth. The segment is estimated to accelerate the global market as most products are available in capsule and tablet form and it is a very viable route of administration.

Opportunities

• Increase in Elderly Population

Increase in elderly population is anticipated to boost the market size. Parathyroid problems are more common in younger adults between the age group of 30 to 40 years and older people. Therefore, the rise in the elderly population is likely to create opportunities for the global market growth. As per the article published in journal of the Endocrine Society, a retrospective survey was conducted from January 1997 to June 2018, which projected that 462 patients were diagnosed with primary hyperparathyroidism and 212 were aged above 65.

• Increased Technological Advancements

Several market players are coming with new technology advancements for the treatment of hypoparathyroidism, For instance, in January 2015, Shire-NPS Pharmaceuticals, Inc. got approval from a product used for treatment of hypoparathyroidism name as NATPARA (parathyroid hormone) that comes as an injection for subcutaneous use.

Restraints/Challenges

• Product Recall by FDA

The product recall by the Food and Drug Administration (FDA) likely hinders the growth of the hypoparathyroidism treatment market. For instance, in September 2019, the Takeda Pharmaceutical Company Limited issued the U.S. recall of NATPARA. The recall is because of a potential issue associated with rubber particulates rising from the rubber septum of the NATPARA cartridge.

• Late Drug Approvals

All the product or drug in hypoparathyroidism come under pharmaceutical or may be directly connected to human, so it needs to undergo some clinical process and have to get the approval from the respective agency before it commercializes in the market that acts as a restraint for the market. 

This global hypoparathyroidism treatment market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hypoparathyroidism treatment market  contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Hypoparathyroidism Treatment Market       

The COVID-19 has impacted the healthcare sector harshly. While, clinical trials for the rare diseases are postponed through 2020 as priority was given to the development of lifesaving drugs, the market for hypoparathyroidism is projected to witness a short-term fall even during 2021.

But, in the post-pandemic era, the market is expected to flourish. Governmental support in the form of funding and grants to support the expansion of new hormonal therapy, the relaxation of lockdown regulations is projected to provide several opportunities for market growth. As a result, the market is anticipated to grow at a steady pace during the forecast period.

Recent Development:

• In March 2021, BridgeBio Pharma declared the positive outcomes from its 2nd stage trial of its new drug encaleret. Regarding hypoparathyroidism treatments, the drug has shown immense effectiveness among patients with autosomal dominant hypocalcemia type 1.

Global Hypoparathyroidism Treatment Market Scope

The global hypoparathyroidism treatment market  is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medication
• Surgery
• Others

Product Type

• Parathyroid Hormone
• Natpara
• Others
• Vitamin D Analogue
• Vitamin D2
• Vitamin D3
• Calcium Supplements

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Hypoparathyroidism Treatment Market Regional Analysis/Insights

The global hypoparathyroidism treatment market  is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global hypoparathyroidism treatment market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to increasing thyroid-related diseases, and increasing initiatives are taken by the pharmaceutical organizations to generate novel formulation.

Asia-Pacific dominates the market due to increasing initiatives taken by the government and pharmaceutical organizations to spread awareness and presence of generic manufacturers.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.    

Competitive Landscape and Global Hypoparathyroidism Treatment Market Share Analysis

The global hypoparathyroidism treatment market  competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hypoparathyroidism treatment market.

Key players operating in the global hypoparathyroidism treatment market  include:

• Teva Pharmaceutical Industries Ltd (Israel)
• Mylan N.V (U.S.)
• Johnsons & Johnsons Services Inc (U.S.)
• F. Hoffman-La Roche Ltd. (Switzerland)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Aurobindo Pharma (India)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc (U.K.)
• Altasciences Clinical Los Angeles Inc (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)

SKU-55197